Albireo Stock Leadership

ALBO
 Stock
  

USD 23.78  0.84  3.66%   

Albireo Pharma employes about 130 people. The company is managed by 25 executives with total tenure of roughly 102 years, averaging almost 4.0 years of service per executive having 5.2 employees per reported executive. Inspection of Albireo Pharma management performance can provide insight into the company performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Albireo Pharma future performance.
Please continue to Trending Equities.
  
  Ronald Cooper  CEO
President CEO, Director
  David Chiswell  Chairman
Chairman of the Board
  Peter Zorn  President
Senior Vice President - Corporate Development, General Counsel and Secretary

Albireo Pharma Return on Sales

(0.53)

Albireo Pharma Management Team Effectiveness

Albireo Pharma has return on total asset (ROA) of (0.2494) % which means that it has lost $0.2494 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (0.9308) %, meaning that it created substantial loss on money invested by shareholders. Albireo Pharma management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return on Investment is estimated to slide to -70.78. The value of Return on Average Assets is estimated to slide to -12.5. Albireo Pharma Net Current Assets as percentage of Total Assets are quite stable at the moment as compared to the past year. The company's current value of Net Current Assets as percentage of Total Assets is estimated at 85.25. Tangible Assets Book Value per Share is expected to rise to 15.21 this year, although the value of Goodwill and Intangible Assets will most likely fall to about 16.5 M.
Weighted Average Shares is expected to rise to about 20.7 M this year. Weighted Average Shares Diluted is expected to rise to about 20.7 M this year

Albireo Pharma Workforce Comparison

Albireo Pharma is rated third in number of employees category among related companies. The total workforce of Health Care industry is presently estimated at about 19,509. Albireo Pharma maintains roughly 130 in number of employees contributing less than 1% to equities under Health Care industry.

Albireo Pharma Profit Margins

The company has Profit Margin (PM) of (2.29) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (2.15) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.02.

Albireo Pharma Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Albireo Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Albireo Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Albireo Pharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Albireo Pharma Benchmark Summation

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Highest value over a specified period line plots max value of Albireo Pharma price series.
.

Albireo Pharma Notable Stakeholders

An Albireo Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Albireo Pharma often face trade-offs trying to please all of them. Albireo Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Albireo Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Ronald Cooper - President CEO, DirectorProfile
David Chiswell - Chairman of the BoardProfile
Peter Zorn - Senior Vice President - Corporate Development, General Counsel and SecretaryProfile
Thomas Shea - CFO, TreasurerProfile
Simon Harford - CFO, TreasurerProfile
Brian Pereira - Independent DirectorProfile
Davey Scoon - DirectorProfile
Stephanie Okey - DirectorProfile
Anne Klibanski - DirectorProfile
Denise ScotsKnight - DirectorProfile
Michael Gutch - DirectorProfile
Roger Jeffs - DirectorProfile
Heather Preston - DirectorProfile
Julia Brown - Independent DirectorProfile
Michelle Graham - Chief OfficerProfile
Kristina Torfgard - VP HeadProfile
Pamela MPH - Chief OfficerProfile
Jason Duncan - Gen OfficerProfile
Pamela Stephenson - Chief Commercial OfficerProfile
Joan Connolly - Chief OfficerProfile
Martha Carter - Chief Regulatory OfficerProfile
Jan Mattsson - MD OfficerProfile
Patrick Horn - Chief Medical OfficerProfile
Paresh Soni - Chief Medical OfficerProfile
PerGoran Gillberg - CoFounder DevelProfile

About Albireo Pharma Management Performance

The success or failure of an entity such as Albireo Pharma often depends on how effective the management is. Albireo Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Albireo management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Albireo management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for 2022
Return on Investment(65.60) (70.78) 
Return on Average Assets(11.58) (12.50) 
Return on Average Equity(19.07) (20.58) 
Return on Invested Capital 23.05  19.26 
Return on Sales(0.49) (0.53) 
The data published in Albireo Pharma's official financial statements usually reflect Albireo Pharma's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Albireo Pharma. For example, before you start analyzing numbers published by Albireo accountants, it's critical to develop an understanding of what Albireo Pharma's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Albireo Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Albireo Pharma's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Albireo Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Albireo Pharma. Please utilize our Beneish M Score to check the likelihood of Albireo Pharma's management to manipulate its earnings.

Albireo Pharma Workforce Analysis

Traditionally, organizations such as Albireo Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Albireo Pharma within its industry.

Albireo Pharma Manpower Efficiency

Return on Albireo Pharma Manpower

Revenue Per Employee335.8 K
Revenue Per Executive1.6 M
Net Loss Per Employee282.4 K
Net Loss Per Executive1.4 M
Working Capital Per Employee205.9 K
Working Capital Per Executive1.1 M
Today, most investors in Albireo Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Albireo Pharma's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's per employee growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Albireo Pharma per employee as a starting point in their analysis.

Per Employee

Albireo Pharma Per Employee Growth Over Time

Net Income Per Employee

(282,435)

Albireo Pharma Net Income Per Employee is quite stable at the moment as compared to the past year. The company's current value of Net Income Per Employee is estimated at (282,435)

Revenue Per Employee

335,837

Albireo Pharma Revenue Per Employee is quite stable at the moment as compared to the past year. The company's current value of Revenue Per Employee is estimated at 335,837
Please continue to Trending Equities. Note that the Albireo Pharma information on this page should be used as a complementary analysis to other Albireo Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try CEO Directory module to screen CEOs from public companies around the world.

Complementary Tools for Albireo Stock analysis

When running Albireo Pharma price analysis, check to measure Albireo Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Albireo Pharma is operating at the current time. Most of Albireo Pharma's value examination focuses on studying past and present price action to predict the probability of Albireo Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Albireo Pharma's price. Additionally, you may evaluate how the addition of Albireo Pharma to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Is Albireo Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Albireo Pharma. If investors know Albireo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Albireo Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
492.3 M
Quarterly Revenue Growth YOY
1.68
Return On Assets
(0.25) 
Return On Equity
(0.93) 
The market value of Albireo Pharma is measured differently than its book value, which is the value of Albireo that is recorded on the company's balance sheet. Investors also form their own opinion of Albireo Pharma's value that differs from its market value or its book value, called intrinsic value, which is Albireo Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Albireo Pharma's market value can be influenced by many factors that don't directly affect Albireo Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Albireo Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Albireo Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Albireo Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.